Introduction {#sec1}
============

Tumor microenvironment (TME) plays an important role in cancer suppression and promotion \[[@B1]\]. As a crucial component of TME, regulatory T cells (Tregs) are responsible for down-regulating chronic inflammation, hindering autoimmune reactions, and maintaining peripheral immunological tolerance \[[@B2]\]. Recently published data demonstrated that Tregs-mediated immunosuppression was a pivotal tumor immune evasion mechanism, and might contribute to the failure of tumor immunotherapy \[[@B5],[@B6]\]. A notable characteristic of Tregs is their expression of the transcription factor forkhead box P3 (FOXP3). The FOXP3 protein, which is encoded from *FOXP3* gene located on the X chromosome at Xp11.23, belongs to the forkhead/winged-helix transcription factor family and functions as a transcriptional repressor to down-regulate cytokine production of Tregs \[[@B7]\]. Several studies reported that FOXP3+ Tregs could infiltrate tumors at higher ratios than other T cells. The accumulation of FOXP3+Tregs in tumors and local lymph nodes could inhibit immune responses and thus result in tumorigenesis with a less favorable prognosis \[[@B8]\]. While Tregs are the major cell type expressing FOXP3 under physiological conditions, it has recently been found that FOXP3 was also expressed in a variety of cancers, such as ovarian, hepatocellular, pancreatic, and thyroid \[[@B11]\]. However, the role of FOXP3 as a tumor suppressor has also been documented. Zuo et al. \[[@B15]\] found that FOXP3 could be expressed in breast epithelial cells but was down-regulated in mammary cancer tissues. Li et al. \[[@B16]\] reported several mutations of this gene in prostate cancer patients and explored the tumor suppressor relationship between the FOXP3 and the Hippo pathways. This reminded us the complex role of FOXP3 and raised the possibility that mutations of *FOXP3* gene might cause immune dysregulation and further cancer development.

Genetic variants, mainly composed of single-nucleotide polymorphisms (SNPs), have been proved to cause alterations in protein function in multiple diseases \[[@B17]\]. Several *FOXP3* SNPs have been unveiled and their role in cancer susceptibility was explored. For example, Fazelzadeh Haghighi et al. \[[@B18]\] enrolled 312 Iranian participants and reported that T allele in rs3761549 (T/C) was correlated with susceptibility to lung cancer. You et al. \[[@B19]\] studied rs3761548 (A/C) polymorphisms in Chinese population and found the frequency of the A allele was significantly lower in endometrial cancer women than that in healthy controls. Another widely studied polymorphism was rs2280883 (C/T). Zheng et al. \[[@B20]\] recruited 1049 breast cancer patients from multiple centers in China but failed to report a significant correlation between allele C mutation and breast cancer risk.

To solve the controversy, a meta-analysis in 2014 was published and suggested that *FOXP3* rs3761549 (T/C) and rs3761548 (A/C) polymorphisms were not associated with the risk of breast cancer, but with the risk of lung cancer and hepatocellular cancer \[[@B21]\]. Unfortunately, it only included five articles with two types of polymorphisms. Since new case--control studies and more polymorphisms were published in recent years, we conducted a comprehensive search of relevant studies with the aim to better clarify the association between *FOXP3* polymorphisms and cancer susceptibility.

Materials and methods {#sec2}
=====================

Literature search {#sec2-1}
-----------------

A comprehensive search of studies published from July 2008 to June 2018 was conducted in online databases of PubMed, Medline (Ovid), Embase, CNKI, Weipu, and Wanfang. The following search query was used: 'FOXP3', 'Forkhead box protein', 'polymorphism', 'mutation', 'variant', 'cancer', and 'malignancy'. The search was updated twice a week until 30 June 2018. Language restrictions were not set and references of identified articles were also assessed for inclusion.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

An eligible study was included if it was consistent with the following criteria: (i) studied *FOXP3* polymorphisms in cancer risk; (ii) analyzed the polymorphisms that appeared in at least two independent articles for potential meta-analysis; (iii) provided sufficient data for extraction and calculation; and (iv) case--control studies based on human patients. When duplicated data appeared in different publications, only the most recent one was included. Meanwhile, studies that did not fulfill the above criteria were excluded.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Potential studies were independently reviewed by two investigators (Y.C. and X.Q.). The following information was extracted from both cases and control groups: first author, year of publication, ethnicity, cancer type, SNPs, control type, genotyping method, adjusted parameters, and genotype distributions. Any discrepancies were resolved through a panel discussion until a consensus was reached.

The Newcastle--Ottawa Scale (NOS) was used to investigate the methodological quality of included studies. Three aspects of selection, comparability, and exposure were carefully evaluated. A score of 0--9 was determined and studies of moderate or high quality were included (score above 5). (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) \[[@B22]\].

Statistical analysis {#sec2-4}
--------------------

To estimate the strength of the association between different *FOXP3* polymorphisms and cancer susceptibility, pooled odds ratios (ORs) and corresponding 95% confidence intervals (C95% Is) were calculated. Since SNPs were considered as binary variables of wild (W) and variant (V) alleles, five comparative models were used as follows: recessive model (VV vs. WW), dominant model (VV+ VW vs. WW), heterozygous model (VW vs. VV+WW), co-dominant model (VV+ VW vs. WW), and allelic model (V vs. W) \[[@B23]\]. Heterogeneity in each study was evaluated based on Higgins *I^2^* test. The random-effects model was applied when *I^2^* \> 50%, indicating the presence of heterogeneity. Otherwise, if the *I^2^* was less than 50%, the fixed-effects model was used \[[@B24]\]. The Z-test was then performed to determine the significance of the pooled ORs where *P*\<0.05 was illustrated as statistically significant. Eventually, the presence of publication bias was evaluated by visually inspecting the funnel plots. When asymmetry was suspected, Egger's test was performed and *P~Egger~* above 0.05 indicating the absence of bias. All statistical analyses were performed using Revman 5.2 software (Cochrane Collaboration, Copenhagen, Denmark) except the Egger's test, which was conducted using STATA 14.0 (StataCorp LP, College Station, TX, U.S.A.).

Results {#sec3}
=======

Search results {#sec3-1}
--------------

As shown in [Figure 1](#F1){ref-type="fig"}, a total of 232 publications were retrieved after the initial research. In our further screening, 82 articles were excluded for duplicity while 104 articles were removed since they were irrelevant to *FOXP3* polymorphisms or cancer risk according to titles and abstracts. Amongst the remaining 46 articles for full-text evaluation, 24 articles were biochemical studies, reviews, or meta-analysis; 6 articles studied non-cancer diseases such as autoimmune diseases; 2 articles analyzed several *FOXP3* polymorphisms that were not studied in other independent researches, resulting in the impossibility of data pooling; 2 articles failed to offer sufficient data for calculation. Therefore, we enrolled 12 articles in this meta-analysis \[[@B18],[@B25]\].

![Flow chart of publication selection](bsr-39-bsr20181809-g1){#F1}

Characteristics of included studies {#sec3-2}
-----------------------------------

The 12 enrolled articles consisted of 19 case--control studies with three *FOXP3* polymorphisms (rs2280883 in four studies, rs3761548 in ten studies, and rs3761549 in five studies) and six cancer types (breast cancer in ten studies, colorectal cancer in one study, endometrial cancer in one study, hepatocellular in two studies, lung cancer in three studies, and thyroid cancer in two studies). Ethnicities included Brazilian, Chinese, Indian, Iranian, and Israeli. The control sources were population-based in two studies and hospital-based in eight studies (two studies failed to mention details on control type). Different genotyping methods were utilized including PCR-PAGE, PCR-restriction fragment length polymorphism (PCR-RFLP), and MS. The NOS showed that four articles were of high quality (NOS score of 8 or 9) and eight were of moderate quality (NOS score of 6 or 7). Adjusted parameters that might affect the cancer susceptibility were also listed ([Table 1](#T1){ref-type="table"}). All studies reported the numbers of corresponding genotypes for both case and control groups as to recessive, heterogeneous, and wild genotypes ([Table 2](#T2){ref-type="table"}).

###### Characteristics of included studies

  Authors                                 Year   Ethnicity   Cancer type      SNPs             Control type   Genotyping method   Adjusted parameters                                                           Study quality (NOS)
  --------------------------------------- ------ ----------- ---------------- ---------------- -------------- ------------------- ----------------------------------------------------------------------------- ---------------------
  Chen et al. \[[@B25]\]                  2013   Chinese     Hepatocellular   rs2280883(C/T)   Hospital       MS                  Age                                                                           8
                                                                              rs3761549(T/C)                                                                                                                    
  Chen et al. \[[@B26]\]                  2014   Chinese     Colorectal       rs3761548(A/C)   Hospital       PCR-PAGE            Age, gender, smoking, alcohol drinking, family history of cancer              8
  Fazelzadeh Haghighi et al. \[[@B18]\]   2015   Iranian     Lung             rs2280883(C/T)   Unknown        PCR-RFLP            Age, gender, family history of cancer                                         6
                                                                              rs3761549(T/C)                                                                                                                    
  He et al. \[[@B27]\]                    2013   Chinese     Lung             rs3761548(A/C)   Hospital       PCR-PAGE            Age, gender                                                                   7
  Banin Hirata et al. \[[@B28]\]          2017   Brazilian   Breast           rs3761548(A/C)   Unknown        PCR-RFLP            Age                                                                           7
  Jahan et al. \[[@B29]\]                 2014   Indian      Breast           rs3761548(A/C)   Hospital       PCR-RFLP            Age, menopausal status,                                                       7
                                                                              rs3761549(T/C)                                      family history of cancer                                                      
  Jiang et al. \[[@B30]\]                 2017   Chinese     Thyroid          rs2280883(C/T)   Hospital       PCR-RFLP            Age, gender                                                                   8
                                                                              rs3761548(A/C)                                                                                                                    
  Lopes et al. \[[@B31]\]                 2014   Brazilian   Breast           rs3761548(A/C)   Population     PCR-RFLP            Age                                                                           8
  Raskin et al. \[[@B32]\]                2009   Israeli     Breast           rs3761548(A/C)   Population     PCR-RFLP            Age                                                                           7
  Tian et al. \[[@B33]\]                  2018   Chinese     Breast           rs3761548(A/C)   Hospital       MS                  Age, menopausal status, procreative                                           7
                                                                              rs3761549(T/C)                                      times                                                                         
  You et al. \[[@B19]\]                   2018   Chinese     Endometrial      rs3761548(A/C)   Hospital       PCR-RFLP            Age, BMI, family history of cancer, menopausal status, history of pregnancy   7
  Zheng et al. \[[@B20]\]                 2013   Chinese     Breast           rs2280883(C/T)   Hospital       MS                  Age, BMI, family history of cancer,                                           7
                                                                              rs3761548(A/C)                                      age at menarche                                                               
                                                                              rs3761549(T/C)                                                                                                                    

Abbreviation: BMI, body mass index.

###### Numbers of genotypes in cases and controls

  SNPs              Authors                                 Year   Ethnicity   Cancer type      Case number   Control number   Case   Control                     
  ----------------- --------------------------------------- ------ ----------- ---------------- ------------- ---------------- ------ --------- ----- ----- ----- -----
  rs2280883 (C/T)   Chen et al. \[[@B25]\]                  2013   Chinese     Hepatocellular   392           372              54     26        312   41    64    267
                    Fazelzadeh Haghighi et al. \[[@B18]\]   2015   Iranian     Lung             30            30               1      14        15    4     13    13
                    Jiang et al. \[[@B30]\]                 2017   Chinese     Thyroid          350           306              13     49        288   10    69    227
                    Zheng et al. \[[@B20]\]                 2013   Chinese     Breast           1049          1091             35     365       649   31    349   711
  rs3761548 (A/C)   Chen et al. \[[@B26]\]                  2014   Chinese     Colorectal       360           400              57     123       180   29    114   257
                    He et al. \[[@B27]\]                    2013   Chinese     Lung             192           259              37     80        75    18    80    161
                    Banin Hirata et al. \[[@B28]\]          2017   Brazilian   Breast           117           300              14     48        55    41    132   127
                    Jahan et al. \[[@B29]\]                 2014   Indian      Breast           202           130              27     160       15    20    106   4
                    Jiang et al. \[[@B30]\]                 2017   Chinese     Thyroid          350           306              19     109       222   11    73    222
                    Lopes et al. \[[@B31]\]                 2014   Brazilian   Breast           50            115              6      17        27    4     66    45
                    Raskin et al. \[[@B32]\]                2009   Israeli     Breast           1444          1458             320    722       402   303   763   392
                    Tian et al. \[[@B33]\]                  2018   Chinese     Breast           559           581              24     198       337   20    173   388
                    You et al. \[[@B19]\]                   2018   Chinese     Endometrial      269           333              13     83        173   21    134   178
                    Zheng et al. \[[@B20]\]                 2013   Chinese     Breast           1049          1091             38     338       673   30    342   719
  rs3761549 (T/C)   Chen et al. \[[@B25]\]                  2013   Chinese     Hepatocellular   388           362              59     28        301   41    88    233
                    Fazelzadeh Haghighi et al. \[[@B18]\]   2015   Iranian     Lung             30            30               1      4         25    0     3     27
                    Jahan et al. \[[@B29]\]                 2014   Indian      Breast           202           130              0      198       4     0     128   2
                    Tian et al. \[[@B33]\]                  2018   Chinese     Breast           560           582              18     157       385   23    187   372
                    Zheng et al. \[[@B20]\]                 2013   Chinese     Breast           1049          1091             32     283       734   34    290   767

Quantitative analysis {#sec3-3}
---------------------

Pooled ORs and corresponding 95% CIs were shown in [Table 3](#T3){ref-type="table"}. Ten studies including 9565 participants were evaluated in rs3761548 (A/C) polymorphisms. For the overall group analysis, only one comparative model indicated an increased cancer risk while the remaining four failed to present any statistical significance (AA vs. AC+CC: OR = 1.38, 95% CI = 1.03, 1.86; AA+AC vs. CC: OR = 1.11, 95% CI = 0.87, 1.42; AC vs. AA+CC: OR = 1.02, 95% CI = 0.86, 1.23; AA vs. CC: OR = 1.39, 95% CI = 0.94, 2.05; A vs. C: OR = 1.16, 95% CI = 0.95, 1.40; [Figure 2](#F2){ref-type="fig"}A). Thus it was impossible to draw a definite conclusion. Since six out of ten studies were focussed on breast cancer and Chinese population respectively, corresponding subgroup analyses were conducted. The results of 7096 participants showed no significant correlation between rs3761548 (A/C) polymorphisms and breast cancer susceptibility. However, an elevated risk in Chinese population was observed by using random-effects models in the enrolled 2779 cases and 2970 controls (AA vs. AC+CC: OR = 1.61, 95% CI = 1.09, 2.39; AA vs. CC: OR = 1.74, 95% CI = 1.05, 2.89; A vs. C: OR = 1.34, 95% CI = 1.00, 1.78; [Figure 2](#F2){ref-type="fig"}B--D). It could be concluded that rs3761548 (A/C) polymorphism was associated with increased cancer risk in Chinese population.

![Representative forest plots of rs3761548 (A/C) polymorphisms and cancer susceptibility\
(**A**) AA vs. AC+CC in overall group analysis. (**B**) AA vs. AC+CC in Chinese group analysis. (**C**) AA vs. CC in Chinese group analysis. (**D**) A vs. C in Chinese group analysis. Abbreviations: df, degree of freedom; M--H, Mantel and Haenszel.](bsr-39-bsr20181809-g2){#F2}

###### Summary of different comparative results of FOXP3 polymorphisms on cancer susceptibility

  SNPs              Genotypes and alleles   Overall and subgroup   Participant number   OR \[95% CI\]         Z value   *P*-value   *I^2^* (%)   Effect model
  ----------------- ----------------------- ---------------------- -------------------- --------------------- --------- ----------- ------------ --------------
  rs2280883 (C/T)   CC vs. CT+TT            Overall                3620                 1.18 \[0.87, 1.59\]   1.08      0.28        0            Fixed
                                            Chinese                3560                 1.23 \[0.91, 1.66\]   1.33      0.18        0            Fixed
                    CC+CT vs. TT            Overall                3620                 0.79 \[0.53, 1.18\]   1.14      0.25        80           Random
                                            Chinese                3560                 0.79 \[0.50, 1.24\]   1.01      0.31        86           Random
                    CT vs. CC+TT            Overall                3620                 0.69 \[0.36, 1.30\]   1.16      0.25        89           Random
                                            Chinese                3560                 0.62 \[0.29, 1.29\]   1.29      0.20        93           Random
                    CC vs. TT               Overall                2671                 1.12 \[0.83, 1.52\]   0.74      0.46        0            Fixed
                                            Chinese                2638                 1.15 \[0.85, 1.57\]   0.91      0.36        0            Fixed
                    C vs. T                 Overall                7240                 0.88 \[0.68, 1.14\]   0.96      0.34        68           Random
                                            Chinese                7120                 0.90 \[0.68, 1.20\]   0.72      0.47        76           Random
  rs3761548 (A/C)   AA vs. AC+CC            Overall                9565                 1.38 \[1.03, 1.86\]   2.15      0.03        67           Random
                                            Breast                 7096                 1.10 \[0.95, 1.28\]   1.30      0.19        8            Fixed
                                            Chinese                5749                 1.61 \[1.09, 2.39\]   2.37      0.02        63           Random
                    AA+AC vs. CC            Overall                9565                 1.11 \[0.87, 1.42\]   0.83      0.41        84           Random
                                            Breast                 7096                 1.02 \[0.92, 1.13\]   0.44      0.66        60           Random
                                            Chinese                5749                 1.35 \[0.98, 1.86\]   1.84      0.07        87           Random
                    AC vs. AA+CC            Overall                9400                 1.02 \[0.86, 1.23\]   0.27      0.79        72           Random
                                            Breast                 7096                 0.95 \[0.78, 1.16\]   0.51      0.61        64           Random
                                            Chinese                5749                 1.17 \[0.94, 1.45\]   1.40      0.01        71           Random
                    AA vs. CC               Overall                5704                 1.39 \[0.94, 2.05\]   1.65      0.10        78           Random
                                            Breast                 3031                 1.06 \[0.89, 1.26\]   0.69      0.49        28           Fixed
                                            Chinese                3,902                1.74 \[1.05, 2.89\]   2.16      0.03        76           Random
                    A vs. C                 Overall                19130                1.16 \[0.95, 1.40\]   1.63      0.10        88           Random
                                            Breast                 13862                1.04 \[0.96, 1.12\]   0.95      0.34        26           Fixed
                                            Chinese                11498                1.34 \[1.00, 1.78\]   1.97      0.05        90           Random
  rs3761549 (T/C)   TT vs. TC+CC            Overall                4424                 1.12 \[0.84, 1.48\]   0.77      0.44        0            Fixed
                                            Breast                 3614                 0.91 \[0.62, 1.34\]   0.48      0.63        0            Fixed
                                            Chinese                4032                 1.11 \[0.83, 1.47\]   0.70      0.49        17           Fixed
                    TT+TC vs. CC            Overall                4424                 0.80 \[0.58, 1.10\]   1.37      0.17        70           Random
                                            Breast                 3614                 0.93 \[0.80, 1.08\]   0.93      0.35        11           Fixed
                                            Chinese                4032                 0.77 \[0.54, 1.10\]   1.45      0.15        84           Random
                    TC vs. TT+CC            Overall                4424                 0.67 \[0.38, 1.18\]   1.38      0.17        88           Random
                                            Breast                 3614                 0.94 \[0.81, 1.10\]   0.77      0.44        0            Fixed
                                            Chinese                4032                 0.61 \[0.32, 1.17\]   1.50      0.13        94           Random
                    TT vs. CC               Overall                3058                 1.00 \[0.75, 1.33\]   0.03      0.97        0            Fixed
                                            Breast                 2371                 0.89 \[0.60, 1.31\]   0.59      0.56        0            Fixed
                                            Chinese                3005                 0.98 \[0.74, 1.31\]   0.11      0.91        0            Fixed
                    T vs. C                 Overall                8848                 0.91 \[0.82, 1.02\]   1.68      0.09        34           Fixed
                                            Breast                 7228                 0.95 \[0.84, 1.07\]   0.90      0.37        6            Fixed
                                            Chinese                8064                 0.88 \[0.74, 1.04\]   1.48      0.14        54           Random

The meta-analysis of the other two polymorphisms failed to show significant association between variant genotypes (or alleles) and cancer susceptibility in corresponding effect models. Briefly, for rs2280883 (C/T) polymorphisms, 3620 participants including 1821 cases and 1799 controls were analyzed. None of the five comparative models displayed any relationship between rs2280883 (C/T) polymorphisms and cancer risk, neither in the overall group analysis (CC vs. CT+TT: OR = 1.18, 95% CI = 0.87, 1.59; CC+CT vs. TT: OR = 0.79, 95% CI = 0.53, 1.18; CT vs. CC+TT: OR = 0.69, 95% CI = 0.36, 1.30; CC vs. TT: OR = 1.12, 95% CI = 0.83, 1.52; C vs. T: OR = 0.88, 95% CI = 0.68, 1.14) nor in the stratified Chinese group analysis (CC vs. CT+TT: OR = 1.23, 95% CI = 0.91, 1.66; CC+CT vs. TT: OR = 0.79, 95% CI = 0.50, 1.24; CT vs. CC+TT: OR = 0.62, 95% CI = 0.29, 1.29; CC vs. TT: OR = 1.15, 95% CI = 0.85, 1.57; C vs. T: OR = 0.90, 95% CI = 0.68, 1.20). Amongst the five studies that focussed on rs3761549 (T/C) polymorphisms, three reported increased cancer risk for mutated genotypes while two reported insignificant results. By pooling the 4424 participants together, no significant correlation was found between T/C mutation and cancer risk. The results of subgroup analysis on breast cancer and Chinese population were consistent with the overall group analysis.

Publication bias {#sec3-4}
----------------

The publication bias was visually examined on the funnel plots generated by Revman 5.2 software. No obvious asymmetry could be observed ([Figure 3](#F3){ref-type="fig"}). We further performed Egger's tests in the three analyses that proposed significant association between rs3761548 (A/C) polymorphisms and cancer susceptibility in Chinese population. The results demonstrated no significant publication bias (*P*\>0.05, data not shown).

![Representative funnel plots of publication bias of rs3761548 (A/C) polymorphisms and cancer susceptibility\
(**A**) AA vs. AC+CC in Chinese group analysis. (**B**) AA vs. CC in Chinese group analysis. (**C**) A vs. C in Chinese group analysis. Abbreviation: SE, standard error.](bsr-39-bsr20181809-g3){#F3}

Discussion {#sec4}
==========

Since alteration of the human immune system can contribute to the development of human cancer, FOXP3 has attracted attention in recent decades as one of the main transcription factors for Tregs, an important participant of immune evasion and surveillance in TME \[[@B34]\]. While imbalance of FOXP3+Tregs has been widely reported in autoimmune diseases such as allergic rhinitis and Graves' disease, the role of FOXP3 in tumorigenesis has long been controversial \[[@B37],[@B38]\]. FOXP3 is able to repress oncogenes while activating additional tumor suppressor genes. Evidences of this dual role include the down-regulation of *MYC* and *HER2* by FOXP3+ Tregs, and the up-regulation of FOXP3 protein in both Tregs and tumor cells in patients with lung cancer and hepatocellular carcinoma \[[@B39]\]. Polymorphisms of the *FOXP3* gene may change FOXP3 protein quantitatively or functionally, thus contributing to predisposition and progression of cancer. To date, several polymorphisms of *FOXP3* have been found including rs2280883, rs3761548, rs3761549, rs2294020, rs2294021, rs5906761, rs5902434 etc \[[@B19],[@B20],[@B32]\]. Their roles in cancer susceptibility remain undetermined due to sample size, ethnicity, and other confounding factors. Here, we conducted a thorough meta-analysis with the aim to address the inconsistencies of existing publications and to draw a more concrete conclusion.

We enrolled 19 case--control studies with 10389 participants in this meta-analysis. Three types of *FOXP3* polymorphisms and six types of cancers were analyzed. The results showed that rs3761548 (A/C) were correlated with cancer susceptibility in Chinese population. The variant AA genotypes and A allele imposed a significant higher cancer risk compared with their counterparts (AA vs. AC+CC: OR = 1.61, 95% CI = 1.09, 2.39; AA vs. CC: OR = 1.74, 95% CI = 1.05, 2.89; A vs. C: OR = 1.34, 95% CI = 1.00, 1.78). Notably, while the breast subgroup analysis failed to present any significance, only one comparative model in the overall group suggested that AA genotypes proposed a 1.38-fold increased risk compared with AC plus CC genotypes (OR = 1.38, 95% CI = 1.03, 1.86). The reason behind this was due to the Lopes et al.'s \[[@B31]\] study of triple-negative breast cancer (TNBC) in Brazil which suggested that AC heterozygous genotype was a protective factor while AA was a risky one. If we excluded it from the meta-analysis, no significant results could be drawn (AA vs. AC+CC: OR = 1.33, 95% CI = 0.99, 1.78). Interestingly, in the article published by You et al. \[[@B19]\], both the variant A allele and mutated genotypes (AA plus AC) in rs3761548 showed a statistically significant protective effect on endometrial cancer, which is contrary to the rest of included studies \[[@B19]\]. If we excluded it from the meta-analysis, an elevated risk was again concluded for A/C mutation in overall cancer risk (AA vs. AC+CC: OR = 1.47, 95% CI = 1.07, 2.00). The intriguing results reminded us the controversial role of *FOXP3* in cancer immunity, especially in different cancer types. As an X-linked gene, the mutated *FOXP3* in females depends on X-chromosome inactivation \[[@B43],[@B44]\]. Whether this rs3761548 position was related to gender-specific cancers or hormone-related cancers such as breast and endometrial cancers remained to be solved. Another relevant point lies in the location of mutated FOXP3 protein in different tumor cells. According to Lopes et al. \[[@B31]\], most TNBC patients had cytoplasmic expression of FOXP3 protein and only some had concomitant perinuclear and/or nuclear expression. The re-localization of FOXP3 protein due to polymorphisms like rs3761548 in certain types of cancer might affect transcription functions and thus cytokine production of Tregs \[[@B45]\].

The results of rs3761549 (T/C) polymorphisms in cancer susceptibility were consistent with the previous meta-analysis \[[@B21]\]. With 4424 participants enrolled, the meta-analysis revealed no significant relationship between rs3761549 (T/C) polymorphisms and cancer risk. However, whether T/C mutations were correlated with increased risk of hepatocellular cancer like previously described remained questionable due to non-repeated researches and limited sample sizes. Specifically, our subgroup analysis stratified by Chinese population indicated a lack of significant association, which was never reported before. Like rs3761548 (A/C), rs3761549 (T/C) polymorphisms were also located in the promoter region of the *FOXP3* gene, which is considered to cause mRNA instability thus affecting FOXP3 production and activity \[[@B46],[@B47]\]. The specific reason why the two types of polymorphisms acted differently in case--control studies is not clear, which is a promising subject for future studies. We also explored the role of rs2280883 (C/T) polymorphisms in cancer risk. The meta-analysis failed to draw a significant conclusion, neither in general sample nor in different subtypes. The less aggressive role of rs2280883 (C/T) polymorphisms might be due to the location, which was in intron 9 very near a conserved transcription region of *FOXP3* gene. This could cause splicing downstream, resulting in a less functional gene. Further researches are needed to consolidate the exact mechanism \[[@B30],[@B48]\].

Despite our efforts to include all the existing publications, some disadvantages of the present meta-analysis should be notified. First, insufficient published studies were enrolled in this meta-analysis. Although the number of participants was so far the largest, more individual studies were still required to determine a precise conclusion, especially for rs2280883 (C/T) polymorphisms. Second, amongst the 19 studies, only six types of cancer were included. It is known that Tregs play a dual role in tumorigenesis. Whether the tumor promotion effect takes place or the contrary is largely due to the biological characteristics of primary cancer \[[@B49]\]. Thus, caution must be paid when explaining the results to other cancers such as the sex-related and hormone-related cancers. Third, the populations of included studies were Chinese, Iranian, Brazilian, Israeli, and Indian, and many other ethnicities like blacks and Caucasians were ignored. This might affect the overall group analysis since we noticed a different result when Chinese population was stratified for rs3761548 (A/C) polymorphisms. Fourth, our evaluation was based on unadjusted results. Risk factors like body mass index, smoking habit, and menstruation status are also known to be important to tumorigenesis in several types of cancer \[[@B50],[@B51]\]. These confounding factors might cause distorted results. Therefore, studies on more types of cancer are needed to help draw a concrete conclusion.

Taken together, based on current articles in databases, our meta-analysis suggested that *FOXP3* rs3761548 (A/C) polymorphisms were associated with cancer risk in Chinese population while no significant correlation was confirmed in rs2280883 (C/T) and rs3761549 (T/C) polymorphisms. To the best of our knowledge, the present study was the most comprehensive one to explore the relationship between *FOXP3* polymorphisms and cancer risk. It is also the first to pool the results of rs2280883 (C/T) polymorphisms and conduct subgroup analysis stratified by ethnicity. Considering the limitations mentioned above, more large-sample researches with diverse ethnicities and cancer types are needed to help reach a consensus.
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